Hayretin Tumani

Summary

Affiliation: University of Ulm
Country: Germany

Publications

  1. ncbi Rare indications of IVIG therapy in neurological diseases based on case reports and small studies
    Hayrettin Tumani
    Dept of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
    J Neurol 253:V66-9. 2006
  2. doi Effect of epileptic seizures on the cerebrospinal fluid--A systematic retrospective analysis
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Germany Electronic address
    Epilepsy Res 114:23-31. 2015
  3. pmc IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 4:e7638. 2009
  4. pmc Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis
    Makbule Senel
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 9:e88680. 2014
  5. ncbi Biochemical markers of autoimmune diseases of the nervous system
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Curr Pharm Des 18:4556-63. 2012
  6. pmc Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases
    Sarah Jesse
    Department of Neurology, University of Ulm, Steinhovelstr 1, 89075, Ulm, Germany
    J Neurol 258:1034-41. 2011
  7. doi CIS case studies
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Ulm, Germany
    J Neurol Sci 287:S7-10. 2009
  8. doi Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Expert Rev Mol Diagn 8:479-94. 2008
  9. doi Cerebrospinal fluid biomarkers in multiple sclerosis
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, Ulm D 89081, Germany
    Neurobiol Dis 35:117-27. 2009
  10. doi Candidate biomarkers of chronic inflammatory demyelinating polyneuropathy (CIDP): proteome analysis of cerebrospinal fluid
    Hayrettin Tumani
    Department of Neurology, University of Ulm, 89081 Ulm, Germany
    J Neuroimmunol 214:109-12. 2009

Collaborators

Detail Information

Publications44

  1. ncbi Rare indications of IVIG therapy in neurological diseases based on case reports and small studies
    Hayrettin Tumani
    Dept of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
    J Neurol 253:V66-9. 2006
    ..Therefore, at this stage treatment with IVIG should be used in conjunction with controlled therapy trials...
  2. doi Effect of epileptic seizures on the cerebrospinal fluid--A systematic retrospective analysis
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Germany Electronic address
    Epilepsy Res 114:23-31. 2015
    ..However, there are only few systematic investigations on the effect of seizures themselves on CSF parameters and the significance of these parameters in differential diagnosis...
  3. pmc IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 4:e7638. 2009
    ..We aimed to evaluate the relevance of MRZR to predict conversion of patients with clinically isolated syndrome (CIS) to MS, and to compare it to oligoclonal bands (OCB) and MRI...
  4. pmc Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis
    Makbule Senel
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 9:e88680. 2014
    ..Since OCB tests are based on non-quantitative and difficult to standardise techniques, measurement of immunoglobulin kappa free light chains (KFLC) may represent an easier to use quantitative test...
  5. ncbi Biochemical markers of autoimmune diseases of the nervous system
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Curr Pharm Des 18:4556-63. 2012
    ..We provide an overview over the widening field of autoimmune diseases of the central and peripheral nervous system and discuss the current state of biomarker research and its relevance for clinical practice...
  6. pmc Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases
    Sarah Jesse
    Department of Neurology, University of Ulm, Steinhovelstr 1, 89075, Ulm, Germany
    J Neurol 258:1034-41. 2011
    ..Extensive elevation of routine parameters is not characteristic and should encourage a re-evaluation of the clinical diagnosis...
  7. doi CIS case studies
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Ulm, Germany
    J Neurol Sci 287:S7-10. 2009
    ..This article presents a number of case studies that illustrate the diversity of presentation of clinically isolated syndrome and the challenges associated with confirming a diagnosis of multiple sclerosis...
  8. doi Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Expert Rev Mol Diagn 8:479-94. 2008
    ..We review recent advances in CSF biomarkers research in CND and thereby focus on markers associated with neurodegeneration...
  9. doi Cerebrospinal fluid biomarkers in multiple sclerosis
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, Ulm D 89081, Germany
    Neurobiol Dis 35:117-27. 2009
    ..A brief update on possible CSF biomarkers that might reflect key pathological processes of MS such as inflammation, demyelination, neuroaxonal loss, gliosis and regeneration is provided...
  10. doi Candidate biomarkers of chronic inflammatory demyelinating polyneuropathy (CIDP): proteome analysis of cerebrospinal fluid
    Hayrettin Tumani
    Department of Neurology, University of Ulm, 89081 Ulm, Germany
    J Neuroimmunol 214:109-12. 2009
    ..The pathophysiological role of these proteins remains to be clarified by further studies...
  11. doi Corticosteroids and plasma exchange in multiple sclerosis
    Hayretin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    J Neurol 255:36-42. 2008
    ..Because of the lack of appropriate studies, PE is not recommended as a permanent disease-modifying strategy in MS patients...
  12. doi 2D DIGE of the cerebrospinal fluid proteome in neurological diseases
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Expert Rev Proteomics 7:29-38. 2010
    ..We review the first studies using 2D DIGE for analysis of the CSF proteome in neurological diseases and discuss advantages, as well as drawbacks, of the methodological approach with special emphasis on CSF-related aspects...
  13. ncbi Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis
    Hayrettin Tumani
    Neurologische Klinik, Universitat Ulm, Rehabilitationskrankenhaus, Oberer Eselsberg 45, 89081, Ulm, Germany
    J Neurol 254:II69-72. 2007
    ..Present data suggest that both immunosuppressive as well as immunomodulatory therapy prevent or delay the onset and severity of cognitive impairment although reversible cognitive deficits can occur...
  14. doi CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis
    H Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Neurosci Lett 452:214-7. 2009
    ..CIS-CIS. For Fetuin-A, our findings could be confirmed by ELISA. The pathophysiological role as well as clinical relevance of these candidate proteins in CIS remains to be further clarified by future studies...
  15. doi Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate
    Hayrettin Tumani
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, Ulm, Germany
    Eur Neurol 65:164-9. 2011
    ..04), 24 (p = 0.02) and 36 months (p = 0.04). Our study indicates that specific patterns of Th1/Th2 cytokines predict the response to GA therapy...
  16. doi [Cerebrospinal fluid-based diagnostics of CT-negative subarachnoid haemorrhage]
    H Tumani
    Abteilung für Neurology, Universitat Ulm, Oberer Eselsberg 45, 89081, Ulm, Deutschland
    Nervenarzt 81:973-9. 2010
    ..Generally, the knowledge of the time flow of CSF changes associated with SAH is essential for a correct interpretation of CSF findings...
  17. ncbi Biochemical markers in CSF of ALS patients
    Sigurd D Sussmuth
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, D 89081 Ulm, Germany
    Curr Med Chem 15:1788-801. 2008
    ..In this review, an updated overview is given on CSF biomarkers related to the pathomechanisms supposed to be participating in the complex disease process of ALS...
  18. pmc The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS)
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Ulm, Germany
    PLoS ONE 5:e11986. 2010
    ....
  19. doi Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?
    Johannes Brettschneider
    Dept of Neurology, Univ of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    J Neurol 256:3-12. 2009
    ....
  20. doi Reduced benefit from mnemonic strategies in early-stage Alzheimer's disease: a brief testing-the-limits paradigm for clinical practice
    Ingo Uttner
    Neurologische Klinik der Universität Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
    J Neurol 257:1718-26. 2010
    ..Our data confirm the finding of an impaired cognitive plasticity already present in very early stages of AD and illustrate the efficiency of a dynamic test approach in identifying incipient dementia...
  21. doi Hypercapnia is a possible determinant of the function of the blood-cerebrospinal fluid barrier in amyotrophic lateral sclerosis
    Sigurd D Sussmuth
    Department of Neurology, Neurologische Klinik der Universität Ulm, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
    Neurochem Res 35:1071-4. 2010
    ..In ALS, an important underlying mechanism might be the influence of the arterial pCO(2) which may alter the CSF flow...
  22. pmc Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage
    Ralf A Linker
    Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany
    PLoS ONE 4:e7624. 2009
    ..In summary, our findings underscore the value of proteome analyses as screening method for stage specific biomarkers and for the identification of new culprits for tissue damage in chronic autoimmune demyelination...
  23. doi Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS)
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Neurosci Lett 468:23-7. 2010
    ..We aimed to identify a characteristic CSF protein pattern that could provide new candidate biomarkers of disease progression in ALS...
  24. ncbi Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Neurosci Lett 404:347-51. 2006
    ..This may be due to a relative deficiency of endogenous CNS EPO in these conditions and/or to a more efficient extraction of free EPO molecules from brain intercellular fluid by increased numbers of EPOR...
  25. ncbi Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum
    Sigurd D Sussmuth
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Neurosci Lett 353:57-60. 2003
    ..Elevation of the CSF/serum albumin quotient occurred in 20% of the cases most likely representing a non-specific finding in ALS...
  26. pmc TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis
    Petra Steinacker
    Department of Neurology, University of Ulm, Ulm, Germany
    Arch Neurol 65:1481-7. 2008
    ..It was demonstrated that different TDP-43 profiles correspond to clinical phenotypes of FTLD or ALS subgroups, and the differential diagnostic potential of TDP-43 was suggested...
  27. doi Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS)
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
    Neurochem Res 33:2358-63. 2008
    ..Further evaluation of the candidate proteins identified here is necessary...
  28. doi MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS
    Lubin Fang
    Department of Neurology, University of Ulm, 89081 Ulm, Germany
    J Neurol Sci 294:51-6. 2010
    ..Our data raises the question whether the skin may function as a biomarker for specific aspects of disease pathology in ALS...
  29. ncbi Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Ulm, Germany
    Mov Disord 21:2224-7. 2006
    ..CSF NfH(SMI35) may therefore be of some value for the laboratory-supported differential diagnosis of atypical parkinsonian syndromes...
  30. ncbi Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients
    Dirk Bahner
    Department of Neurology, Hospital of Fulda, Pacelliallee 4, D 36043 Fulda, Germany
    Neurosci Lett 326:125-8. 2002
    ..IL-12p70 did not increase during treatment. These data show that immunological processes may also play a role in primary progressive MS and that IFNbeta-1b has an immunomodulating effect in this particular MS subtype...
  31. ncbi The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Ulm, Germany
    Dement Geriatr Cogn Disord 21:291-5. 2006
    ....
  32. ncbi Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b
    Andreas Bitsch
    Neurologische Klinik, Ruppiner Kliniken GmbH, Fehrbelliner Strabe 38, 16816, Neuruppin, Germany
    J Neurol 251:1498-501. 2004
    ..Like patients with relapsing remitting or secondary progressive multiple sclerosis, PPMS patients may be at risk of an autoimmune response during IFNB treatment...
  33. ncbi Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    Neurosci Lett 416:257-60. 2007
    ..Low concentrations of CSF EPO seem to point towards a rapid progression of disease that may be associated with a poorer prognosis...
  34. ncbi Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease
    Karin Widl
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
    Neurochem Res 32:1163-8. 2007
    ..The establishment of age-related reference values in a large cohort of controls will improve the interpretation of future CSF EPO evaluations in neurological diseases...
  35. doi Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease
    Sarah Jesse
    Department of Neurology, University of Ulm, Ulm, Germany
    J Alzheimers Dis 17:541-51. 2009
    ....
  36. doi Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS)
    Lubin Fang
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany
    J Neurol Sci 285:62-6. 2009
    ..Our findings indicate a general upregulation of MMP-9 in ALS. MMP-9 seems to play a role in both neurodegeneration and skin changes in ALS and could thus be a common factor linking otherwise distant aspects of disease pathology...
  37. doi Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration
    Petra Steinacker
    Department of Neurology, University of Ulm, Ulm, Germany
    J Neural Transm (Vienna) 116:1169-78. 2009
    ..We propose to expand this study to larger patient groups comprising followed up cases with known neuropathology...
  38. doi Cognitive impairment in superficial siderosis of the central nervous system: a case report
    Ingo Uttner
    Department of Neurology, University of Ulm, Ulm, Germany
    Cerebellum 8:61-3. 2009
    ..Probable mechanisms leading to the characteristic cognitive impairment in superficial siderosis are discussed...
  39. doi Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases
    Johannes Brettschneider
    Department of Neurology, University of Ulm, Ulm, Germany
    J Neuroimmunol 217:95-101. 2009
    ..Interestingly, the anti-GAGA4 assay may also differentiate between primary progressive MS (PPMS) and RRMS/SPMS patients, since nearly all PPMS patients were negative for the assay...
  40. doi Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease
    Petra Steinacker
    Department of Neurology, University of Ulm, Germany
    Proteomics 10:81-9. 2010
    ..The selective increase of ubiquitin in CSF of CJD patients might point to an involvement of ubiquitin in pathophysiological process...
  41. doi Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial
    F Fazekas
    Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, A 8036 Graz, Austria
    Neurology 71:265-71. 2008
    ..We therefore set out to test two different doses of a new formulation of immunoglobulin termed IGIV-C 10% for suppression of both clinical and MRI disease activity as well as safety...
  42. ncbi International quality control survey of neurochemical dementia diagnostics
    Piotr Lewczuk
    Department of Psychiatry and Psychotherapy, University of Erlangen Nuremberg, Erlangen, Germany
    Neurosci Lett 409:1-4. 2006
    ..Although the results of this quality control survey are promising, the quality of measurements has to be further optimized...
  43. ncbi Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis
    Maryna Yushchenko
    Dept of Neurology, Georg August University, Gottingen, Germany
    J Neurol 250:1224-8. 2003
    ..The suppression of MMP-9 by IFN-beta1b indicates that this drug is immunomodulatory active in PPMS patients. Further studies are necessary to test if IFN-beta exerts a beneficial effect in PPMS...
  44. doi Glutaminyl cyclase activity is a characteristic feature of human cerebrospinal fluid
    Anastassia Gontsarova
    Institute of Pathophysiology, University of Greifswald, Karlsburg, Germany
    Clin Chim Acta 389:152-9. 2008
    ..However, proteins and peptides are potential substrates of proteases and other enzymes. Proteolysis and enzymatic modification may lead to their degradation and modification...